triiodothyronine has been researched along with Aortic Diseases in 3 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Aortic Diseases: Pathological processes involving any part of the AORTA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cyclosporine may suppress transplant arteriosclerosis; however, it also raises plasma cholesterol, which could promote the disease." | 7.69 | Dose-dependent suppression of transplant arteriosclerosis in aorta-allografted, cholesterol-clamped rabbits. Suppression not eliminated by the cholesterol-raising effect of cyclosporine. ( Andersen, HO; Hansen, BF; Holm, P; Nordestgaard, BG; Stender, S, 1997) |
| "Cyclosporine may suppress transplant arteriosclerosis; however, it also raises plasma cholesterol, which could promote the disease." | 3.69 | Dose-dependent suppression of transplant arteriosclerosis in aorta-allografted, cholesterol-clamped rabbits. Suppression not eliminated by the cholesterol-raising effect of cyclosporine. ( Andersen, HO; Hansen, BF; Holm, P; Nordestgaard, BG; Stender, S, 1997) |
| " This study aimed to evaluate whether thyroid hormones predicts early (30 days) and mid-term (12 months) aorta-related adverse events (ARAE) and readmissions (ARAR) in patients after TEVAR." | 1.46 | Association of Thyroid Function with Early/Mid-term Aorta-Related Adverse Events and Readmissions after Thoracic Endovascular Aortic Repair. ( Chen, X; He, Z; Lu, N; Ma, X; Tan, X; Xu, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, N | 1 |
| He, Z | 1 |
| Xu, T | 1 |
| Chen, X | 2 |
| Ma, X | 1 |
| Tan, X | 1 |
| Chen, WJ | 1 |
| Lin, KH | 1 |
| Lai, YJ | 1 |
| Yang, SH | 1 |
| Pang, JH | 1 |
| Andersen, HO | 1 |
| Holm, P | 1 |
| Stender, S | 1 |
| Hansen, BF | 1 |
| Nordestgaard, BG | 1 |
3 other studies available for triiodothyronine and Aortic Diseases